Trial Profile
Proof-of-concept Randomized, Double-blind, Phase IIa Study to Show Feasibility, Validate Assays and Approaches, and Explore Dosing and Safety of Belimumab in Pulmonary Emphysema Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Emphysema
- Focus Pharmacodynamics; Proof of concept
- Acronyms BOTEGA
- 04 Apr 2022 Status changed from recruiting to completed.
- 28 Oct 2021 Planned End Date changed from 1 Jul 2021 to 1 Jul 2023.
- 28 Oct 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Jul 2022.